The University of Maine

DigitalCommons@UMaine
General University of Maine Publications

University of Maine Publications

11-12-2021

University of Maine Institutional Biosafety Committee (IBC)
Protocol Registration Form
Office of Research Compliance, University of Maine

Follow this and additional works at: https://digitalcommons.library.umaine.edu/univ_publications
Part of the Higher Education Commons, and the History Commons

Repository Citation
Office of Research Compliance, University of Maine, "University of Maine Institutional Biosafety
Committee (IBC) Protocol Registration Form" (2021). General University of Maine Publications. 2259.
https://digitalcommons.library.umaine.edu/univ_publications/2259

This Form is brought to you for free and open access by DigitalCommons@UMaine. It has been accepted for
inclusion in General University of Maine Publications by an authorized administrator of DigitalCommons@UMaine.
For more information, please contact um.library.technical.services@maine.edu.

Institutional Biosafety Committee (IBC) Protocol Registration Form

Page 1 of 15

University of Maine Institutional Biosafety Committee (IBC)
Protocol Registration Form
Registration Type:
☐ New IBC Registration
☐ Exempt Protocol (See II-B)
☐ Amendment to IBC Protocol No.
☐ Renewal to IBC Protocol No.
Registration is required prior to use of recombinant, synthetic nucleic acid activities, biological materials (human and
animal blood, body fluids, tissues), animal, human and plant pathogens, and imported live biological materials. Required
by National Institutes of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid
Molecules, University of Maine Institutional Biosafety Program, and related Federal, State and University policies.
Technical information relating to this registration is considered confidential.
All Sections of this registration must be completed, with supporting documentation included. This registration
document is meant to provide sufficient detailed information regarding each Biohazardous/Recombinant DNA research
project so that it may be adequately reviewed by the University of Maine Institutional Biosafety Committee. Do not
provide excess information. Discuss with the Institutional Biosafety Program as needed. Please refer to the IBC website
for more information.
Use Microsoft Word to fill in the form. Email the completed request to the Office of Research Compliance,
mailto:umric@maine.edu

I.

Administrative Data
A.

Principal Investigator:

Name:

Email Address:

Department:

Phone #:

B.

Project Information:

Project Title for IBC Registration:
Granting Agency Proposal Title:
Does the project have external funding? ☐ Yes ☐ No If ‘Yes’ then indicate Granting Agency/Project # below.
Granting Agency:
C.

ORS Project #:

Amendment Type:
1.

Major Amendments

All major changes require a complete registration form and full committee review.
☐ Change in scope of research
Reason for Major Change(s):

☐ Additional research projects/procedures ☐ Change of Principal Investigator

Institutional Biosafety Committee (IBC) Protocol Registration Form
2.
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Minor Changes:

Dependent upon the type of changes, full IBC Review may not be required. Sections III and VI may need to be
updated. Contact the Institutional Biosafety Program.
☐ Additional Title
☐ Add/Change Lab Location. Update Section VI.A.
☐ Add or Delete Personnel: Update Section VI.B. Use
additional sheets if necessary.

Update Section III for the following:
☐ Animal Strains
☐ Animal Material
☐ Human Material
☐ Plant Material
☐ Cell Lines
☐ Genetic Constructs
☐ Others (explain):

Description of Minor Change(s):

D.

Summary of Biomaterials

This project uses: (Check all that apply)
☐ Biologically Derived Toxins
☐ Prions and Related Biomolecules
☐ Recombinant Activity/Synthetic Nucleic Acid
☐ Microorganisms
☐ Infectious Materials
☐ Cell Lines/Tissues
☐ Invertebrate Animals
☐ Vertebrate Animals

☐ Plants/Plant Parts/Algae
☐ Large-scale (>10 L) production
☐ Environmental Samples (soil, water)
☐ Diagnostic/Clinical Samples (blood, urine, etc.)
☐ Human Origin Material (contact IRB)
☐ Engineered Nanomaterials
☐ Select Agents (www.selectagents.gov)
☐ DURC Concerns or Other

Description of Minor Change(s):

II.

Project Classification
A.

Brief Project Description

Briefly describe the purpose of the project using non-scientific language (in terms for the average citizen). This project
description, title, and PI name will be in the publicly available IBC minutes.
Please restrict to 3-5 sentences.

Institutional Biosafety Committee (IBC) Protocol Registration Form
B.
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Determine if Exempt per NIH Guidelines, Section III-F

Item #
8.1

Does this project…
Yes No
ONLY includes rDNA manipulation involving E. coli K12, S. cerevisiae, and B. subtilis host
☐
☐
vector systems (except for DNA from Risk Group 3, 4, or restricted agents)? IF YES,
THEN this registration is exempt, and you may Proceed to Section III. Exempt
registrations are reviewed by an expedited process. An Import and Use permit is required if
importing into the state.
8.2
NOT USE organisms or viruses (PCR or sequencing only, no inoculation into cells, cloning
☐
☐
into competent cell, viral vectors, etc.)?
8.3
ONLY consist entirely of DNA segments from a single non-chromosomal or viral DNA
☐
☐
source, though one or more of the segments may be a synthetic equivalent?
8.4
ONLY consist entirely of DNA from a prokaryotic host including its indigenous plasmids or
☐
☐
viruses when propagated only in that host (or a closely related strain of the same species), or
when transferred to another host by well-established physiological means?
8.5
ONLY consist entirely of DNA from a eukaryotic host including its chloroplasts,
☐
☐
mitochondria, or plasmids (but excluding viruses) when propagated only in that host (or a
closely related strain of the same species)?
8.6
ONLY consist entirely of DNA segments from different species that exchange DNA by
☐
☐
known physiological processes, though one or more of the segments may be a synthetic
equivalent? A list of such exchangers can be found in the NIH Guidelines Section IV-C-1-b(1)-(c), Major Actions. For a list of natural exchangers that are exempt from the NIH
Guidelines, see NIH Guidelines Appendices A-I through A-VI, Exemptions under Section
III-F-5--Sub lists of Natural Exchangers.
8.7
Present NO significant risk to health or the environment as determined by the NIH Director,
☐
☐
with the advice of the RAC, and following appropriate notice and opportunity for public
comment? (see NIH Guidelines Section IV-C-1-b-(1)-(c), Major Actions). Please refer to
NIH Guidelines Appendix C, Exemptions under Section III-F-6 for other classes of
experiments which are exempt from the NIH Guidelines.
8.8
ONLY involve the purchase or transfer of transgenic rodents for experiments that require
☐
☐
Biosafety Level 1 containment (The Purchase or Transfer of Transgenic Rodents, Appendix
C-VII)?
8.9
ONLY involve the breeding of two different transgenic rodents or the breeding of a
☐
☐
transgenic rodent and a non-transgenic rodent with the intent of creating a new strain of
transgenic rodent that can be housed at Biosafety Level 1 containment?
IF ALL YES boxes are checked above, then this registration is Exempt, and you may Proceed to Section
III. Exempt registrations are reviewed by an expedited process.
8.10
ONLY involve the breeding of two different transgenic rodents or the breeding of a
☐
☐
transgenic rodent and a non-transgenic rodent with the intent of creating a new strain of
transgenic rodent that can be housed at Biosafety Level 1 containment
AND
Both parental rodents can be housed under BL1 containment;
☐
☐
AND
neither parental transgenic rodent contains the following genetic modifications:
☐
☐
(i) incorporation of more than one-half of the genome of an exogenous eukaryotic
virus from a single family of viruses; OR
(ii) incorporation of a transgene that is under the control of a gamma-retroviral long
terminal repeat(LTR);
AND
the transgenic rodent that results from this breeding is not expected to contain
☐
☐
more than one-half of an exogenous viral genome from a single family of viruses.
(Generation of BL1 Transgenic Rodents via Breeding - Appendix C- VIII).
IF ALL YES boxes are checked, then this registration is Exempt, and you may Proceed to Section III.
Exempt registrations are reviewed by an expedited process.
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Item
#
C.1
C.1a
C.2
C.3
C.4
C.5
C.6
C.7
C.8
C.8a
C.8b
C.9
C.10
C.11
C.12
C.13
C.14
C.15
C.16
C.17
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Description of Non-Exempt Projects:

Does this project … (Please check all boxes that apply)
☐ Include deliberate transfer of a drug resistance trait to microorganisms that are not known to acquire
the trait naturally (Section III-A*)?
If answered “YES” for C.1 (above), could such a transfer compromise the use of the drug to
☐
control disease agents in humans, veterinary medicine, or agriculture?
☐ Include cloning toxin molecules with an LD50 of less than 100 nanograms per kilogram body weight
(Section III-B*)?
☐ Include experiments involving the deliberate transfer of recombinant DNA, synthetic nucleic acids, or
DNA or RNA derived from recombinant DNA, into one or more human research participants (Section
III-C*)?
☐ Include experiments using Risk Group 2, Risk Group 3, Risk Group 4, or Select Agents as host-vector
systems (Section III-D-1*)?
☐ Include experiments in which DNA from Risk Group 2, Risk Group 3, Risk Group 4, or Select Agents
is cloned into nonpathogenic prokaryotic or lower eukaryotic host-vector systems (Section III-D-2*)?
☐ Include experiments involving the use of replication-competent recombinant DNA or RNA viruses or
defective DNA or RNA viruses in the presence of helper virus in tissue culture systems (Section III-D3*)?
☐ Include experiments with recombinant influenza virus?
☐ Include experiments involving whole animals in which the animal’s genome has been altered by
introduction of DNA into the germ line (i.e. transgenic animals) (Section III-D-4, III-E-3*)?
If answered “YES” for C.8 (above), does the animal contain a transgene encoding more than
☐
50% of the genome of an exogenous eukaryotic virus?
If answered “YES” for C.8 (above), is the transgene under the control of a gamma-retroviral
☐
promoter?
Include
experiments
involving viable rDNA-modified microorganisms tested on animals (Section III☐
D-4, III-E-3*)?
☐ Include experiments involving genetically engineered whole plants (Section III-D-5, III-E-2*)?
☐ Include experiments involving more than 10 liters of culture (Section III-D-6*)?
☐ Include experiments involving the formation of recombinant DNA molecules containing no more than
two-thirds of the genome of any eukaryotic virus and propagated in tissue culture (Section III-E-1*)?
☐ Uses Select Agents (defined by HHS/CDC/USDA Select Agent Program)
☐ Require biosafety level 3 containment (BSL3)?
☐ Dual Use Research of Concern Agents or Toxins?
☐ Requires Federal or State import permit?
☐ Uses unmodified Genomic Material only (e.g., DNA or RNA for sequence or expression analysis)?
D.

Suggested NIH Classification

Derived from NIH Guidelines.
Applicant-determined designation may change upon IBC review.
Item
#
D.1
D.2
D.3
D.4
D..5
D.6
D.7
D.8

Please check all boxes that apply:
☐ Use of animal cells/cell lines or tissues (e.g. tissue culture research)
☐ Use of human cells/cell lines or tissues (e.g. Human blood, 293 cell
lines, CSF)
☐ Transfer of Drug Resistance trait to microorganisms
☐ Use or cloning of toxin molecule genes
☐ Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or
restricted agent
☐ Use of virus or viral particles
☐ Propagating culture volumes exceeding 10 liters
☐ Creation or Use of c-DNA/genomic libraries

NIH Guidelines reference
II-A-3, Appendix C-1
II-A-3 Revision Date:
01/01/2018
III-A-1-a
III-B-1
III-D-1, 2
III-D-3, III-E-1
III-D-6
III-E, III-F
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D.9
D.10
D.11
D.12

☐
☐
☐
☐

D.13

☐

D.14
D.15
D.16
D.17

☐
☐
☐
☐

III.

Cloning and vector construction in bacteria and yeasts
Use of rDNA molecules for detection purposes (e.g. probes)
Expression of rDNA products in cultured cells
Administration of rDNA product into humans (e.g. Gene Transfer
Protocol)
Administration of rDNA material into animals (e.g. transformed cells,
vectors)
Experiments involving transgenic rodents
Experiments involving whole transgenic plants
This is an EXEMPT project, per Section II.B.
Select Agent or Toxins
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III-E, III-F
III-F
III-E, III-F
III-C-1
III-D-4
III-E-3
III-D-5
III-F

Description of Biological Materials
A.

Nanomaterials

The CDC defines a technology as engineered nanotechnology only if it involves all the following:
● Research and technology development involving structures with at least one dimension in the range of 1 to100
nanometers (nm), frequently with atomic/molecular precision
● Creating and using structures, devices, and systems that have unique properties and functions because of their
nanometer-scale dimensions
● The ability to control or manipulate on the atomic scale
● NIEHS Nanomaterials
● OSHA Nanotechnology
● CDC Nanotechnology Guidance & Publications
This project uses engineered nanomaterials? ☐ Yes ☐ No
IF YES, THEN please describe the nanomaterials and how they will be used:
B.

Biotoxins

Does the project require possession, use, or transfer of acute biological toxins (mammalian LD50 <100 μg/kg body
weight) or toxins that fall under the Federal Select Agent Guidelines, as well as the organisms, both natural and
recombinant, which produce these toxins? ☐ Yes ☐ No
IF Yes THEN Complete this section, describe the work and relevant Standard Operating Procedures in an attachment.
Name of Toxin:
1.
2.
3.
4.

Current Inventory:

Attach a biotoxin-specific plan for storage, handling, waste disposal/neutralization.
☐ Biological toxin will be commercially acquired or ☐ produced in the laboratory
☐ Experiments involve cloning a biological toxin gene
☐ Will be used in animals (dosing)
C.

Recombinant and Synthetic Nucleic Acids

Refer to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules
Does this work involve Recombinant/Synthetic Nucleic Acid Molecule Activity?
☐ Yes - Complete this section. ☐ No - Do not complete this section. Go to Section III.D.

Institutional Biosafety Committee (IBC) Protocol Registration Form
1.

Source of Nucleic Acid Sequence

Name (Gene/siRNA Name, e.g.
GFP green fluorescent protein)

2.
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Source (species, strain, cell line,
cultivar, Vendor/Supplier)

Function of the genetic element

Nature of the Modified DNA

Describe the functional and structural elements of the recombinant DNA, including the regulatory and/or coding
regions, percentage of the entire genome, promoter, synthetic antisense sequence, etc. Will this element be expressed?
What is your risk assessment of the sequence (tumor suppressor, oncogene, etc.)?

3.

Vectors

List the cloning and delivery vector(s) used, including selectable marker(s), reporter genes(s), oncogenes, promoters,
packaging cell line, assay system for detection, quantification, and/or host range of packaged viral vector. Vector
packaged in competent cells (E.coli), other host microbes must have an import permit. Detail the Risk Attenuation
Phenotype (e.g. replication defective, helper virus, disarmed, K-12 derived, potential for reversion, etc.).

**Reference any literature from commercially available vectors**
Name
(include the genus species
if derived from
plasmid/virus)

4.

Type
(plasmid,
phage, virus,
etc.)

Source
(Vendor/Supplier)

Generation
(1st , 2nd,
3rd, 4th,
etc..)

Recipient Organism

Specify the type of organism, species, strain, cell line, or cultivar receiving the nucleic acid.

Risk Attenuation
Phenotype

Institutional Biosafety Committee (IBC) Protocol Registration Form
5.
☐ Yes ☐ No

Will you express a toxin or oncogene?

If Yes, please specify:

6.
☐ Yes ☐ No
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Will the vector host range be altered?

If Yes, describe:

7.
Will the project use infectious DNA/RNA viruses, defective DNA/RNA viruses, or
phagesin the presence of helper virus in a tissue culture system?
☐ Yes ☐ No

If yes, provide details on the pathogenicity, host range or generation system:

D.
Microorganisms
Identify and describe microorganisms to be employed by this protocol. If none, please indicate N/A or leave blank.
Plant
Pathogen

Produce
Toxin

In Vivo Use

Receive
rDNA
material

Source

Animal
Pathogen

Human
Pathogen

Microorganism Name (genus,
species, strain name)

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐

☐
☐
☐
E.

☐
☐
☐

☐
☐
☐

☐
☐
☐

☐

☐

☐

☐

☐

☐

Cell Lines and Tissues

Identify and describe cells and tissues to be employed by this protocol. If none, please indicate N/A or leave blank.
Receive rDNA
construct

Receive
microorganism

☐

☐

☐

☐

☐

☐

Does this Cell line contains latent, adventious, or inherent microorganisms or virus (e.g., HEK and adenovirus)?
☐ Yes ☐ No

Chemically
altered

In Vivo Use

Source

Passage (Primary/
Established/
Immortalized)

Technical Name
(e.g. NIH3T3)

Cell Lines/Tissue Name

☐
☐

Institutional Biosafety Committee (IBC) Protocol Registration Form
F.
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Animals
1.

Will you use animals?

☐ Yes (Complete this section.)
☐ Vertebrate
☐ Invertebrate
☐ No (Proceed to Part III.G)
If Yes is checked, you may also need IACUC approval. See the IACUC website.
2.

List all animal species and research locations

Animal Species/Strains

3.

Location of Animal Research

ABSL
designation

Hazards from Animals

Do any of the strains or manipulated animals present a hazard that would require more than ABSL-1 (BSL1-N) housing?
☐ Yes (complete entire animal part of IBC registration)
☐ No
4.

List all transgenic animals

Include animals to be acquired and/or breeding/cross-breeding. (Attach an additional sheet if needed. If none, indicate
N/A or leave blank.)
Background Strain:

5.

Line Designation to be Crossed

Source of Line

Description of transgenic animals

Please check all boxes that apply:
III.F.5.a ☐ The animals contain more than one-half of the genome of an exogenous eukaryotic virus.
III.F.5.b ☐ If cross-breeding, the offspring have transgenes under the control of LTR and contain more than
one-half of the exogenous viral genome
III.F.5.c ☐ Transgenes are under control of gamma-retroviral long terminal repeat (LRT).
6.

Acquisition and Breeding of Transgenic Animals

Please check all boxes that apply:
III.F.6.a ☐ Transgenic animals will be purchased
Vendor:
III.F.6.b ☐ Transgenic animals will be generated in-house
III.F.6.c ☐ A colony of transgenic animals will be maintained
III.F.6.d ☐ Transgenic animals will be cross-bread to generate new strains

Institutional Biosafety Committee (IBC) Protocol Registration Form
7.
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Will biological materials* be inserted/inoculated/introduced?

☐ Yes (Describe below)
☐ No

*If biological material is infectious, use of BSC, negative pressure and restricted entry during manipulation is REQUIRED

8.

Will there be a potential of biological material being shed from the animal?

☐ Yes (Describe below)
☐ No

9.

Does animal waste/bedding require decontamination?

☐ Yes (Attach reference and recommended protocol)
☐ No
10.

PPE Use

Describe PPE and biosafety containment use by Laboratory Animal Services. Respond in the Risk Management
Section, VI.D.
11.

Will you use venomous, dangerous, endangered or threatened wild animals?

☐ Yes (List below, describe PPE and Biosafety Containment in attachment, and attach a copy of the permits from
DLNR, CITES/NFWS.)
☐ No

G.

Plants and Derived Biological Materials
1.

Will you use plants, including plant parts, plant cell lines, but excluding fungi?

☐ Yes (Complete this section. Attach relevant plant use SOP.)
☐ Whole Plant
☐ Plant Part
☐ Plant cell lines
☐ No (Proceed to Part IV.)

Institutional Biosafety Committee (IBC) Protocol Registration Form
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2.

Will you use commercially available de-regulated transgenic plants only?

3.

Will biological materials be inserted/inoculated/introduced?

☐ Yes
☐ No
☐ Yes (Describe below)
☐ No

4.

List all plant species and research locations.

IF field testing provide location (field allocation no., GPS location of all four corner points).
Plant Species
(include genus
species or variety)

Has this plant been
altered?
How?

Location of Research

Greenhouse
/Screen house
(Yes/No)

BSL of
Greenhouse

Growth
Chamber/
Room
(Location)

Field Location:
5.

Will you be using poisonous, dangerous or endangered/threatened plants?

☐ Yes (List below, describe PPE and Biosafety Containment in attachment, and attach a copy of the permits from
DLNR, CITES/NFWS.)
☐ No

IV.

Experimental Design

Provide a concise description or summary of your project procedures, placed in sequential order of performance. Attach
an additional sheet if needed. **Please do not attach entire protocols.**

Institutional Biosafety Committee (IBC) Protocol Registration Form
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Risk Assessment
A.

Risk Group Classification:

The PI should review Appendix B of the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic
Acid Molecules and propose a risk group.
☐
☐
☐
☐
☐

Does not apply. No microorganisms, pathogens, or biomaterial are being used that will cause human, plant, or
animal disease.
RG1: Agents that are not associated with disease in healthy adult humans. This group includes a list of animal
viral etiologic agents in common use. These agents represent no or little risk to an individual and no or little
risk to the community.
RG2: Agents that are associated with human disease which is rarely serious and for which preventive or
therapeutic interventions are often available. These agents represent a moderate risk to an individual but a low
risk to the community.
RG3: Agents that are associated with serious or lethal human disease for which preventive or therapeutic
interventions may be available. These agents represent a high risk to an individual but a low risk to the
community.
RG4: Agents that are likely to cause serious or lethal human disease for which preventive or therapeutic
interventions are not usually available. These agents represent a high risk to the individual and a high risk to the
community. NO RG4 RESEARCH IS AUTHORIZED AT THE UNIVERSITY OF MAINE
SYSTEM.
B.

Host Range of the Biological Material(s).

Required only if RG2 or RG3 was selected above:

C.

Support for Risk Classification

Identify biosafety risks. What would be the impact of a release to the environment? Extract, condense and describe
the pertinent biosafety content from your protocol. Cite supporting references and/or URLs as needed (assist the
reviewers):

D.

Hazardous Process?

☐ Centrifuge
☐ Sonication

☐ Sharps
☐ Tissue Harvesting

☐ Animal
☐ Pipetting

☐ Injection
☐ None

☐ Other (please state):

E.

Possible Exposure Routes?

☐ Ingestion
☐ Mucous Membrane
☐ Other (please state):

☐ Percutaneous (i.e. needle puncture)
☐ Inhalation
☐ None

☐ Direct Contact

Institutional Biosafety Committee (IBC) Protocol Registration Form
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Risk Management
A.

Designated Work Areas

Building

B.

Room Number

Biosafety
Designation
(BSL-, ABSL-,
BL-P, BL-N…)

Date of Most
Recent
Biosafety
Inspection

Movement and Storage

Concisely describe protocol-specific movement and secure storage plans. Attach an additional sheet if needed.

C.

Personnel Training.

Detail all personnel performing manipulations. The PI must be fully trained. (Separate sheet may be attached if
necessary.)
Name

Type of Training

D.

Date of Training

Personal Protective Equipment (PPE)

☐ Safety Glasses/Goggles ☐ Gloves
☐ Hair Bonnet ☐ Disposable Booties

☐ Lab Coat
☐ Disposable Lab Gown
☐ Surgical Mask
☐ N-95 Respirator*

☐Other (Describe)
*Requires respirator use clearance, fit testing, and training.
E.

Engineering Controls

☐ Biosafety Cabinet
☐Other (Describe)

☐ Fume Hood Centrifuge

☐ Rotor Covers

☐ PAPR*

Institutional Biosafety Committee (IBC) Protocol Registration Form
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Equipment Certifications

Type of Equipment
Biosafety Cabinet

Manufacturer/Model

Location

Last Certification Date

Any HEPA equipment
Aerosol generating
equipment
Autoclave
How often is an autoclave quality control test (biological indicator test)
performed?
TYPE of Biological Indicator: ☐ spore ☐ Class 5 integrator
Laminar Flow Clean
Bench

☐Annually ☐ Quarterly
☐ Monthly ☐Not routine

DO NOT USE a Laminar Flow Clean Bench for Infectious Agents. Laminar Flow Clean Benches are not for worker
or environmental protection. They are for product protection only
G.

Decontamination and Waste Disposal

In addition to any attached protocol-specific information, describe how biohazardous materials, waste, carcasses, and
bedding will be disinfected and disposed. Include type of chemical disinfectant, concentration, and time.

VII.

Incident Response Plan

A.
Does a written protocol-specific incident response plan exist?
Incidents would include spill, exposure, injury, fire reporting, security breech, etc.
☐ Yes (you need NOT attach)
☐ No
B.
Item #
B.1
B.2

Occupational Health Program

Question
Are personnel enrolled in an occupational health or medical surveillance program?
Respiratory protection occupational health program (required for any person using a
respirator)
B.3
Tuberculosis testing / surveillance (required for persons who enter the tuberculosis lab)
B.4
Blood-borne pathogen training and HepB vaccine
B.5
Other (vaccine, medical surveillance, etc.)
Describe. Attach an additional sheet if needed.

Yes
☐
☐

No
☐
☐

☐
☐
☐

☐
☐
☐

Institutional Biosafety Committee (IBC) Protocol Registration Form
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Select Agents and Toxin/Tier 1

This research uses Tier 1 select agents and toxins (see Select Agents and Toxins List).
☐ Yes
☐ No

IX.

Dual Use Research of Concern (DURC)

Biological research is considered ‘dual-use research of concern’ if the methodologies, material or results could be used in
a manner to cause public harm. To ensure all research is given due consideration as to whether the planned experiments
include DURC, the following questions must be answered. (See NIH Dual Use Research of Concern).
Dual Use Questionnaire
Yes No
Will an intermediate or final product of your research make a vaccine less effective or ineffective?
☐
☐
Will the intermediate or final product of your research confer a drug resistance trait to
☐
☐
microorganism(s) in the study that could compromise the use of appropriate or conventional drugs to
control these microorganism(s) as disease agents in humans, veterinary medicine, or agriculture?
Will your work enhance the virulence of a pathogen or render a non-pathogen virulent?
☐
☐
Will the results of your work increase the transmissibility of any pathogen?
☐
☐
Will your research result in the alteration of the host range of the pathogen?
☐
☐
Will your research result in an intermediate or final product that may prevent or interfere with the
☐
☐
diagnosis of infection or disease?
Does your research enable weaponization* of an agent or toxin?
☐
☐
Will synthetic biology** techniques be used to construct a pathogenic organism, toxin or potentially
☐
☐
harmful intermediate product?
Even if your planned research does not involve any of the above eight criteria, and recognizing that
☐
☐
your work product or results of your research could conceivably be misused, is there the potential for
your data/product to be readily used to cause public harm?
*In this context, weaponization refers to the enhanced dispersion, deliverability, survivability or pathogenesis of a
potentially harmful agent or toxin.
**Synthetic biology includes, but is not limited to, techniques of molecular biology, chemistry, and genetics that would
allow for the de novo synthesis or reverse engineering of genes, gene products or entire functional organisms.

X.

Federal/State Permits and Other Approvals
A.

Federal and State Permits

Do the activities/materials for this project require a federal/state permit? ☐ Yes ☐ No
If yes, please provide the permit information below and include a copy of the current permits with this registration
application.
●
●
●

There will be No Authorization without a copy of the permit or authorization.
For NEW protocols, if a permit is pending, you must submit a copy of the final approved permit to the
Biosafety Office before you may begin work.
For RENEWAL protocols, please provide most current approved permit with the registration form.

Type (CDC,
USDA)

Permit #

Biological Materials listed on permit

Importation /
Inoculation

Exp. Date

Institutional Biosafety Committee (IBC) Protocol Registration Form
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Other UMaine Review Committee Approvals:

Is this work subject to ☐ UMaine IACUC, ☐ IRB, ☐Radiation Safety (EHSO), ☐ Chemical and Physical Hazards
Committee, or ☐ Office of Export Control? Please provide basic information in the table below. The PI should submit
applications to these other review entities as appropriate.
Protocol #

Exempted
☐

Protocol Title

Exp. Date

☐
☐

XI.

Miscellaneous

Item #
A.
B.

Question
Will your experiments involve large scale culture? (bioreactors or >10 Liters in one container)
Will your experiments involve transfer of an antibiotic resistance gene into the host in
addition to those contained in vectors?
C.
Will you be using human pluripotent stem cells derived from human embryos (human
embryonic stem cells) or human fetal tissue (human embryonic germ cells)?
D.
Will your research/experiment involve the need to share confidential or proprietary
information?
E.
Will your research/experiment involve the need to transfer materials and/or data to other
institutions, organizations, or foreign countries?
If any Yes box was selected for items A - C, ensure information is provided that addresses those items.

Yes
☐
☐

No
☐
☐

☐

☐

☐

☐

☐

☐

The information provided may be shared with other institutional programs and offices for their review and
assessment. It is intended that the disclosure of information to other UMaine compliance entities will not
interfere with the independent IBC review and approval process.

XII.

Certification

As Principal Investigator, I understand the risks associated with recombinant and synthetic nucleic acid molecules, use of
biologically hazardous materials (human pathogens, human blood, body fluids, or tissues, animal pathogens, blood, body
fluids or tissues, plant pathogens), and imported biological materials.
I will notify the UMaine Office of Research Compliance and Institutional Biosafety Officer immediately should related
activity produce an unanticipated product that increases virulence or toxicity, or otherwise confers a phenotypic change
that could be biologically hazardous. Furthermore, I certify I have read the relevant sections of the NIH Guidelines and
CDC/USDA requirements (see links above), have or will have appropriately trained and advised my staff of the
requirements outlined in the NIH Guidelines or CDC/USDA requirements prior to initiation of the project,
acknowledge I have reviewed this form, and I am responsible for this project.
I am familiar with and agree to abide by all provisions of UMaine IBC, US CDC, Maine BLS, NIH, USDA and other
applicable State and Federal guidelines/regulations pertaining to the proposed project. I understand that I bear the
responsibility for ensuring that all personnel are adequately trained and informed of any risks with the research activity.
I agree to comply with all applicable requirements pertaining to:
● Reporting of all personnel exposures of regulated biological material
● Reporting any transgenic/knockout/knock-in/ biological material release/escape.
● Transport/transfer of for import/export of biological commodities
The information in this application is accurate and correct.
Principal Investigator (Print)
Principal Investigator (Signature)

Date

